Results 271 to 280 of about 143,384 (302)

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

Ca-A Cancer Journal for Clinicians, 2011
Timothy A Yap, Johann Sebastian de Bono
exaly  

Target protection as a key antibiotic resistance mechanism

Nature Reviews Microbiology, 2020
Daniel N Wilson, Vasili Hauryliuk, Gemma Atkinson   +2 more
exaly  

6 Target Costing

2022
Thorsten Knauer, Friedrich Sommer, Arnt Wöhrmann   +2 more
openaire   +1 more source

Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors

Ca-A Cancer Journal for Clinicians, 2011
Kiran K Turaga
exaly  

Recent Progress in the Management of Advanced Renal Cell Carcinoma

Ca-A Cancer Journal for Clinicians, 2007
Brian I Rini
exaly  

A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015

Ca-A Cancer Journal for Clinicians, 2007
Carolyn D Runowicz
exaly  

Target Costing

2008
openaire   +1 more source

Angiogenesis Inhibitors: Current Strategies and Future Prospects

Ca-A Cancer Journal for Clinicians, 2010
Kristina M Cook, William D Figg
exaly  

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

Nature Reviews Microbiology, 2009
Lanying Du, Yuxian He, Yusen Zhou
exaly  

Therapeutic strategies to target RAS-mutant cancers

Nature Reviews Clinical Oncology, 2018
Ryan B Corcoran
exaly